Federal Officials Extend Pause on Johnson & Johnson Vaccine Over Rare Clotting Cases
U.S. regulators and an independent expert panel extend a pause on the Johnson & Johnson vaccine after six women develop rare blood clots. Health officials warn the delay leaves vulnerable populations at risk while the White House downplays the impact on overall vaccination goals.
Federal health regulators and an independent expert panel extend a pause on the Johnson & Johnson COVID-19 vaccine after six women between the ages of 18 and 48 develop a rare blood clotting disorder. The CDC and FDA initially recommend the suspension out of an abundance of caution, noting that the clots occur in veins that drain blood from the brain and happen alongside low platelet levels. One person dies, and while no proven link exists between the shot and the condition, the Advisory Committee on Immunization Practices votes to keep the pause in place to gather more data.
Health officials warn that extending this delay carries severe consequences for the most vulnerable Americans. Dr. Nirav Shah, president of the Association of State and Territorial Health Officials, tells the expert panel that failing to make a decision functions as a decision in itself. Because the Johnson & Johnson shot requires only one dose and standard refrigeration, it serves as an ideal option for rural communities and areas with limited healthcare infrastructure, leaving these locations to navigate the logistical challenges of the two-dose Pfizer and Moderna vaccines.
The White House downplays the long-term effects of the suspension on the national vaccination effort. COVID-19 response coordinator Jeff Zients states that the Johnson & Johnson shot accounts for less than five percent of administered vaccines in the United States, insisting the pause will not significantly derail the Biden administration's distribution plans. Meanwhile, other nations follow the American lead, as both the European Union and South Africa place their own stocks of the single-dose vaccine on hold.